- Ipriflavone
-
- $42.00
-
2026-05-30
- CAS:35212-22-7
- Purity: 99.60%
- Supply Ability: 10g
- Ipriflavone
-
- $42.00
-
2026-05-29
- CAS:35212-22-7
- Purity: 99.60%
- Supply Ability: 10g
- Ipriflavone
-
- $42.00
-
2026-05-29
- CAS:35212-22-7
- Purity: 99.60%
- Supply Ability: 10g
|
| | Ipriflavone Basic information |
| | Ipriflavone Chemical Properties |
| Melting point | 116-120 °C(lit.) | | Boiling point | 363.04°C (rough estimate) | | density | 1.2170 (rough estimate) | | refractive index | 1.4700 (estimate) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMF:20.0(Max Conc. mg/mL);71.35(Max Conc. mM)
DMF:PBS (pH 7.2) (1:4):0.2(Max Conc. mg/mL);0.71(Max Conc. mM)
DMSO:33.11(Max Conc. mg/mL);118.11(Max Conc. mM)
Ethanol:1.5(Max Conc. mg/mL);5.35(Max Conc. mM) | | form | powder to crystal | | color | White to Almost white | | Merck | 14,5074 | | InChI | InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3 | | InChIKey | SFBODOKJTYAUCM-UHFFFAOYSA-N | | SMILES | C1OC2=CC(OC(C)C)=CC=C2C(=O)C=1C1=CC=CC=C1 | | LogP | 4.245 (est) | | CAS DataBase Reference | 35212-22-7(CAS DataBase Reference) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 24/25-36/37/39-27-26 | | WGK Germany | 2 | | RTECS | DJ3100500 | | HS Code | 29329990 | | Storage Class | 11 - Combustible Solids |
| | Ipriflavone Usage And Synthesis |
| Description | Ipriflavone, a derivative of isoflavone, is a calcium metabolism regulator useful in the
treatment of primary and secondary osteoporosis, as well as disorders of osteogenesis. It
appears to be without significant side-effects. | | Chemical Properties | white powder | | Originator | Chinoin (Japan) | | Uses | 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one (Ipriflavone) has been used as a model drug in a study to functionalize the mesoporous bioactive glasses (MBG). Study suggested that since ipriflavone is a hydrophobic anti-osteoporotic drug, it easily attaches to the surface of MBG and results in long-term drug delivery. | | Uses | anabolic | | Definition | ChEBI: Ipriflavone is a member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women. It has a role as a bone density conservation agent. It is a member of isoflavones and an aromatic ether. | | Brand name | Osten | | benefits | Ipriflavone is used clinically to treat osteoporosis. Bodybuilders also use ipriflavone, but enough experimental data supports this purpose. It has been shown to have anti-inflammatory and antioxidant activity. It helps to reduce bone loss, increase bone density, and reduce the risk of developing osteoporosis. It has also been found to help reduce neuroinflammation . In addition, it has been found to help reduce the risk of certain types of cancer, improve cognitive function and reduce the risk of depression. | | General Description | 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one (Ipriflavone), a synthetic flavonoid, is reported to stimulate the activity of osteoblasts. It is reported to promote the deposition of calcium and the formation of mineralized nodules by newborn rat calvarial osteoblast-like (ROB) cells as well as the activity of alkaline phosphatase. Ipriflavone, an isoflavone derivative, is a new drug used to decrease bone loss in osteoporosis. | | Side effects | Ipriflavone should be taken under medical supervision only. It can produce side effects such as stomach pain, diarrhoea, dizziness, etc. It may have a sudden increase in the WBC count if administered for six months or more. When the treatment with Ipriflavone is on, it is suggested that the WBC count should be monitored. | | Synthesis | General procedure for the synthesis of epoxyflavone from 7-hydroxy-3-phenyl-4H-benzopyran-4-one and 2-bromopropane: To a 30 ml DMF solution of 2.50 g of 7-hydroxy-3-phenyl-4H-benzopyran-4-one (10.5 mmol) was added 1.80 g of anhydrous K2CO3 (13.0 mmol) and 3.0 ml of 2-bromopropane ( 32.0 mmol). The reaction mixture was stirred at 80 °C for 4 h. After completion of the reaction, the mixture was poured into ice water. The precipitate was collected by filtration and washed with a small amount of water and dried to give the crude product. The crude product was purified by Sephadex LH-20 column chromatography (eluent: chloroform:methanol = 7:3), and the fraction containing the target product was collected, concentrated, and recrystallized from acetone to give 1.05 g of epsilon-flavonoid crystals with a yield of 42% (w/w) and a melting point of 110-111 °C. The product structure was determined by 1H NMR. The structure of the product was confirmed by 1H NMR, 13C NMR and mass spectrometry (MS).1H NMR (DMSO-d6) δ: 1.33 (-CH3), 1.34 (-CH3), 4.86 (m, 1H, >CH2-), 7.05 (dd, 1H, J = 8.86, 2.20 Hz, 6-H), 7.16 (d, 1H, J = 2.50 Hz, 8-H), 7.38 (t, 1H, J = 6.78 Hz, 4'-H), 7.44 (t, 2H, J = 7.76, 1.6 Hz, 3',5'-H), 7.59 (d, 2H, J = 8.09, 1.6 Hz, 2',6'-H), 8.22 (d, 1H, J = 8.86 Hz, 5-H), 8.46 (s, 1H 128.1 (C-3',5'), 128.9 (C-2',6'), 132.0 (C-4'), 154.0 (C-2), 157.5 (C-9), 162.0 (C-7), 174.1 (C-4). , 279.5 (M-H)-. Elemental analysis (C18H16O3) calculated values: C, 77.12; H, 5.75. measured values: C, 76.50; H, 5.69. | | in vitro | Ipriflavone inhibits the proliferation and DNA synthesis of MDA-231 cells and blocks the ligand-induced phosphorylation of Tyr(845) of the EGFR. Ipriflavone does not promote apoptosis of MDA-231 cells. Ipriflavone also promotes the deposition of calcium and the formation of mineralized nodules by newborn rat calvarial osteoblast-like cells as well as the activity of alkaline phosphatase. | | in vivo | Ipriflavone ameliorated the host inflammatory response associated with activation of NLRP3 inflammasomes at the implantation site, which was characterised by inflammatory cell infiltration and reduced levels of the pro-inflammatory cytokine interleukin-1β. Daily oral administration of ipriflavone at 12 mg/mouse significantly inhibits the development of new osteolytic bone metastases and the progression of established osteolytic lesions, prolonging the life of tumor-bearing mice. Ipriflavone reduces the number of osteoclasts at the bone-cancer interface with no severe adverse effects on the host. 1-month treatment with ipriflavone increases bone density and improves the biomechanical properties of adult rat male bones without altering mineral composition. | | References | [1] Journal of Labelled Compounds and Radiopharmaceuticals, 1999, vol. 42, # 5, p. 497 - 504
[2] Bioorganic and Medicinal Chemistry, 2003, vol. 11, # 18, p. 4069 - 4081
[3] Patent: WO2004/2470, 2004, A1. Location in patent: Page/Page column 22-23
[4] Patent: US3949085, 1976, A |
| | Ipriflavone Preparation Products And Raw materials |
|